<div id="readability-page-1"><p><strong>Repare Therapeutics</strong> <span>(RPTX<span> 0.65%</span>)</span>, a clinical-stage precision oncology company, released its second quarter 2025 earnings on August 8, 2025. The most notable news from the release was its GAAP net loss per share of $0.39, a much narrower loss than the consensus GAAP estimate of -$0.56. This outperformance was largely the result of a $5.7 million gain from the sale of its technology platforms, rather than recurring collaboration payments. In contrast, GAAP revenue was $0.3 million, substantially below the expected $5.0 million (GAAP) and also below the $1.1 million (GAAP) reported in the prior year. Expense reductions were a highlight, as research and development spend (GAAP) declined year-over-year and general and administrative costs dropped as well, confirming a shift toward a leaner, partnership-driven business model. Overall, the quarter featured aggressive cost control and progress on licensing deals, but little growth in underlying revenue.</p><div><table><tbody><tr><th>Metric</th><th>Q2 2025</th><th>Q2 2025 Estimate</th><th>Q2 2024</th><th>Y/Y Change</th></tr><tr><td>EPS (GAAP)</td><td>$(0.39)</td><td>$(0.56)</td><td>$(0.82)</td><td>52.4 %</td></tr><tr><td>Revenue (GAAP)</td><td>$0.3 million</td><td>$5.0 million</td><td>$1.1 million</td><td>(72.7 %)</td></tr><tr><td>Net R&amp;D Expense</td><td>$14.3 million</td><td></td><td>$30.1 million</td><td>(52.5 %)</td></tr><tr><td>General &amp; Administrative Expense</td><td>$6.0 million</td><td></td><td>$8.3 million</td><td>(27.7 %)</td></tr><tr><td>Cash, Cash Equivalents &amp; Marketable Securities</td><td>$109.5 million</td><td></td><td></td><td>N/A</td></tr></tbody></table></div><p> Source: Analyst estimates for the quarter provided by FactSet. </p><h2 id="about-repare-therapeutics-and-its-business-model">About Repare Therapeutics and Its Business Model</h2><p>Repare Therapeutics is a biotechnology company specializing in precision oncology. Its core strategy revolves around synthetic lethality, developing drugs that target cancer cells based on their unique genetic vulnerabilities. The company’s main technology platform, called SNIPRx, uses advanced gene-editing techniques to identify promising targets for cancer therapies.</p><p>Recently, Repare has focused on maximizing value by entering licensing partnerships and out-licensing parts of its technology. Its near-term success depends on developing successful clinical-stage assets, smartly leveraging its proprietary technology for partnerships, and maintaining strict cost control. Key success factors include progressing its in-house clinical programs and generating milestone payments from collaborators.</p><h2 id="quarter-in-review-licensing-clinical-updates-and-expense-control">Quarter in Review: Licensing, Clinical Updates, and Expense Control</h2><p>This period marked a major operational transition for Repare. The primary driver of the positive earnings surprise was a $5.7 million gain from selling parts of its discovery platform to DCx Biotherapeutics, which provided a $1 million upfront payment in May 2025, with $3 million in near-term payments expected and a 9.99% equity stake in DCx as of May 2025. In July, Repare announced a licensing deal with Debiopharm for lunresertib, its PKMYT1 inhibitor therapy. The arrangement delivers $10 million upfront and up to $257 million in future milestones, as disclosed in July 2025, with Debiopharm now financing and leading further development. While these deals generated immediate cash, most upside rests on future events outside Repare’s direct control.</p><p>Collaboration revenue with Bristol-Myers Squibb contributed $0.3 million, reflecting an option fee for one new drug target, a decline from $1.1 million in the prior year. The GAAP revenue was $0.3 million compared to $1.1 million in the prior year.</p><p>On the clinical front, both of Repare’s in-house programs remained in early stages. The POLAR trial for RP-3467, a drug targeting the enzyme DNA polymerase theta (Polθ) in selected solid tumors, is enrolling patients but released no new results this period. The LIONS study for RP-1664, a PLK4 kinase inhibitor for tumors with high TRIM37, completed enrollment of 29 patients but has not released new safety or efficacy data. Both studies are expected to report initial findings by the end of 2025, and no regulatory filings were advanced this quarter.</p><p>GAAP R&amp;D expenses dropped to $14.3 million, down from $30.1 million in the prior year, while general and administrative spending fell by 27.7% year-over-year. The company also recorded $3.4 million in restructuring charges.</p><h2 id="financial-outlook-and-what-to-watch-ahead">Financial Outlook and What to Watch Ahead</h2><p>Repare did not provide clear financial guidance for the remainder of the year or for fiscal 2026. Management discussed anticipated receipts from its new licensing agreements and highlighted two expected clinical data releases late in 2025 as the next potential value drivers. However, it did not set specific revenue or expense targets for future quarters.</p><p>Looking ahead, investors will be watching for results from the company’s POLAR and LIONS studies, as these could affect both the value of Repare’s retained assets and its licensing potential. Another important factor will be the success of partnerships and out-licensing arrangements, since most near-term income depends on partner-driven milestones and payments instead of organic revenue growth. The company’s ongoing search for strategic alternatives, partnerships, or possible asset sales has no disclosed timeline. RPTX does not currently pay a dividend.</p><p><em>Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.</em></p>                                                                            </div>

RPTX

<p>Repare Therapeutics (RPTX) reported a narrower Q2 2025 GAAP net loss of $0.39 per share, better than the expected $0.56 loss, primarily due to a $5.7 million gain from technology sales. However, GAAP revenue fell to $0.3 million, significantly below the $5.0 million estimate and down from $1.1 million year-over-year. The company focused on cost control, with R&D expenses dropping 52.5% to $14.3 million. Future growth hinges on clinical trial results and licensing agreements, with no specific financial guidance provided for the remainder of the year.</p>

Repare (RPTX) Q2 Loss Narrows 52%